New Findings from University of Brescia in the Area of Biologics Described [Definition of the Clinical Characteristics of Patients with Moderate and Severe Atopic Dermatitis for Whom Narrow-Band UVB (NB-UVB) and Medium-Dose UVA1 Phototherapies...].

Keywords: Atopic Dermatitis; Bioengineering; Biologics; Biotechnology; Complementary and Alternative Medicine; Dermatitis; Dermatology; Genetic Engineering; Genetically-Engineered Proteins; Health and Medicine; Phototherapy; Skin Diseases and Conditions; Skin and Connective Tissue Diseases and Conditions EN Atopic Dermatitis Bioengineering Biologics Biotechnology Complementary and Alternative Medicine Dermatitis Dermatology Genetic Engineering Genetically-Engineered Proteins Health and Medicine Phototherapy Skin Diseases and Conditions Skin and Connective Tissue Diseases and Conditions 990 990 1 05/22/23 20230526 NES 230526 2023 MAY 26 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Fresh data on biologics are presented in a new report. Medium-dose UVA1 and NB-UVB phototherapies remain useful for the treatment of AD patients with a baseline EASI score lower than 24.4 and 24.7, respectively, and a medical history of flares followed by prolonged periods of complete or near-complete remission.". [Extracted from the article]